AI models like Qure.ai’s qXR or Google’s DeepMind classifier are trained on millions of chest radiographs. Artificial intelligence is becomi...
 |
| AI models like Qure.ai’s qXR or Google’s DeepMind classifier are trained on millions of chest radiographs. |
Tuberculosis kills more people each year than HIV and malaria combined. Despite being preventable and curable, more than 10 million people fall ill with the disease annually, with the majority of cases occurring in Africa and Southeast Asia. The challenge has never been a lack of medical knowledge, but rather limited access to diagnostic infrastructure and delayed detection that allows the infection to spread undetected in communities.
The rise of AI-driven radiology
Enter AI screening platforms such as Qure.ai, Zebra Medical Vision, and Google’s DeepMind Health initiative. These systems can interpret chest X-rays in seconds — highlighting suspicious lesions or patterns consistent with TB. One of Qure.ai’s solutions, qXR, has already been deployed in over 70 countries. It operates offline, making it ideal for mobile X-ray units used in rural settings without stable internet access.
“AI allows us to bridge the diagnostic gap in regions where radiologists are scarce,” said Dr. Lucica Ditiu, Executive Director of the Stop TB Partnership. “It’s not a replacement for doctors — it’s an amplifier of their reach.”
In Uganda, local health workers use mobile vans equipped with AI-powered X-ray machines to screen hundreds of patients daily. In less than a minute, the system flags potential TB cases and syncs them to the national health registry for follow-up. Similar programs in India and Bangladesh have reduced diagnostic time from weeks to minutes, ensuring that patients start treatment earlier and transmission rates decline.
The Stop TB Partnership reports that more than 40% of undiagnosed TB cases in 2024 were identified through AI-assisted mobile screening initiatives. The speed and scalability of these deployments could mark a turning point in the fight against TB — particularly as AI models continue to improve through global data sharing.
How the technology works
AI models like Qure.ai’s qXR or Google’s DeepMind classifier are trained on millions of chest radiographs. These models learn to detect pixel-level anomalies that correspond with TB-related lung damage. The system then assigns a “TB likelihood score,” visualized through color heatmaps for clinicians to review. Over time, the AI refines its accuracy through continual retraining with verified medical data.
While the results are promising, experts warn that accuracy varies depending on patient demographics and X-ray quality. There are also ethical and regulatory considerations around medical AI — particularly regarding data privacy, algorithmic bias, and accountability for misdiagnoses. Governments are working with the WHO’s AI in Health guidelines to create standards ensuring safe, equitable deployment.
To scale effectively, private companies and public health organizations are forming cross-sector collaborations. Qure.ai, for instance, has partnered with the Bill & Melinda Gates Foundation and the U.S. Agency for International Development (USAID) to expand AI-driven TB detection in high-burden countries. These efforts combine local clinical expertise with cloud-based analytics and real-time reporting dashboards to support national TB programs.
The success of AI in tuberculosis detection has opened the door to broader applications. Similar models are now being adapted to detect pneumonia, lung cancer, and COVID-related lung damage. In the near future, AI may serve as a universal triage tool, instantly analyzing medical images in areas with no access to radiologists — essentially democratizing diagnostic care.
Beyond respiratory diseases, AI is being integrated into digital pathology and microbiology, where it assists in identifying bacterial strains, predicting drug resistance, and optimizing treatment regimens — turning once manual diagnostic processes into scalable, data-driven systems.
Despite its technical sophistication, the greatest value of AI in TB screening lies in its human impact. In rural Africa, South Asia, and Latin America, thousands of patients are being diagnosed early enough to begin treatment — preventing transmission to families and communities. For clinicians, it means more time spent caring for patients instead of interpreting images under pressure.
The integration of artificial intelligence into TB screening demonstrates how technology can become a public health ally. With proper oversight, investment, and inclusivity, AI could help make tuberculosis — once the world’s deadliest infectious disease — a relic of the past.
